The Effects of ICD Coding Transition on Neurologic Diagnoses
The transition from the International Classification of Disease (ICD)-9 to ICD-10 coding system may impact estimates of neurologic disease prevalence.
The transition from the International Classification of Disease (ICD)-9 to ICD-10 coding system may impact estimates of neurologic disease prevalence.
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Investigators sought to examine the safety, pharmacokinetics, and pharmacodynamics of risdiplam in infants with type 1 spinal muscular atrophy.
The phase 3 SPR1NT trial is an ongoing open-label, single-arm study evaluating onasemnogene in presymptomatic patients (≤6 weeks of age) with a genetic diagnosis of SMA and 2 or 3 copies of survival motor neuron 2 gene.
In Part 2 of the trial, patients 2-25 years of age received either risdiplam for 24 months or placebo for 12 months followed by risdiplam for 12 months.
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
Researchers sought to discover whether SRP-9001 would aid large muscle groups, as measured with quantitative MRI and spectroscopy.
Treatment with casimersen led to a statistically significant increase in dystrophin production in skeletal muscle from baseline to week 48.
A panel of international experts provided new evidence-based recommendations for the management of myasthenia gravis, including new guidance for thymectomy and medical treatment.
Tori Rodriguez, MA, LPC, discusses the progression of care for patients with Duchenne muscular dystrophy during the COVID-19 pandemic.